Today news
About the same in other media
Dr Reddy's share price declines 5% post Q4 earnings performance: Net profit declines 3% sequentially
Reading now: 264
₹1,307 crore for the quarter ended March (Q4FY24), rising 36% year-on-year over ₹159.2 crore in the year ago quarter. However the net profit was 3% lower sequentially compared to ₹13,738 crore seen in the December'2023 quarter.
Dr Reddy's North America sales contributing 45% to overall revenues though grew 29% year-on-year to ₹3262.6 Crore , however the same was 3% lower sequentially. Dr Reddy's sales in the US market has been driven by the launch of multiple myeloma treatment drug Revlimid generics, nevertheless contributions are likley to have peaked with entry of competitors and thereby declining sequentially.
Read more on livemint.comAbout this in other media
Bitcoin Price Prediction: BTC Nears $62,000 Amid Fed’s Hawkish Stance and PPI Report; CPI Ahead cryptonews.com /4 days ago
Gold prices flat ahead of key US inflation data economictimes.indiatimes.com /5 days ago
Gold price declines ahead of US inflation data, silver gains marginally livemint.com /6 days ago
Show more
The website fvbb.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
